Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 28;21(2):112–124. doi: 10.1038/s41579-022-00809-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Springer Nature Limited 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

PMC Copyright notice

Fig. 1 — a, Spike mutational profiles for each variant of concern (VOC) with the receptor binding domain (RBD) also shown for BA.1, BA.2, and BA.4 and BA.5. b, Geometric mean fold reduction in neutralization (mFRN) values of monoclonal antibodies (mAbs) against VOCs relative to reference or control variants. Means are calculated from published studies reporting neutralization data on clinically approved mAbs against VOCs. Data for the associated single studies are shown in Supplementary Fig. 2. Full data sets are available in Supplementary Data File 1, and confidence statistics in Supplementary Data File 2. Colours depict the strength of resistance: dark red, strong (mFRN > 100); red, moderate (mFRN = 10–100); light red, mild (mFRN = 3–10); light grey, no resistance (mFRN = 1–3); dark grey, increased sensitivity (mFRN < 1). All mFRN values are given to two significant figures. Amu + Rom, amubarvimab + romlusevimab; Bam + Ete, bamlanivimab + etesevimab; Cas + Imd, casirivimab + imdevimab; Cil + Tix, cilgavimab + tixagevimab; n.d., no neutralization data reported for the antibody–variant pair at the time of writing; NTD, amino-terminal domain.